An interventional study of embolization therapy in Knee Osteoarthritis (Knee OA), sponsored by Next Biomedical Co., Ltd.. Recruiting at 3 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-11-19.
Sponsored by Next Biomedical Co., Ltd. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Osteoarthritis, Knee with a site in Belgium — 6 open to participants now, 11 under way, none of them phase 3. Osteoarthritis, Knee · Belgium.
Among the 46 studies in Osteoarthritis, Knee with a site in Belgium, this one is the 22nd largest by planned enrollment of the 38 interventional ones that give a count, is one of 3 that started in 2025, is one of 25 with no phase, reaches primary completion later than 7 of the 10 other live ones, and was the 43rd registered.
3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.
Browse Osteoarthritis, Knee studies →6 of the 46 studies in Osteoarthritis, Knee with a site in Belgium are open now. Recruiting first, the newest first:
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18+
Medisch Centrum Latem · Sites in Belgium
Ages 18–85
Ziekenhuis Oost-Limburg · Sites in Belgium, Netherlands
Ages 18+
Sint-Trudo Hospital · Sites in Belgium
Ages 18+
Vrije Universiteit Brussel · Sites in Belgium
Ages 50+
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 72 is close to the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 86 across the 38 interventional studies, 190 across the 8 observational. Of the 29 that completed or were terminated, 7 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 46 have an industry lead sponsor. The 10 most frequent:
Next Biomedical Co., Ltd. is the lead sponsor of 10 studies on the registry; 5 are open to participants now.
Next Biomedical Co., Ltd. has 1 study filed under Osteoarthritis, Knee — fewer than ten, so there is no comparison to draw.
5 of the studies in Osteoarthritis, Knee with a site in Belgium that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05387473Vrije Universiteit BrusselAdded Value of Cognitive Behavioural Therapy for Insomnia in Persons With Knee Osteoarthritis | 2026-12 |
| NCT07465601Medisch Centrum LatemDaily Activity and Clinical Outcome Measurement of Arthrosamid® Administration in Symptomatic Knee Osteoarthritis. | 2027-01-31 |
| NCT06930677Next Biomedical Co., Ltd.Study in Patients With Knee Osteoarthritis Treated by Embolization Using NBGM200 | 2027-02 |
| NCT06891807Medisch Centrum LatemComparison of Image Based Robotic Total Knee Arthroplasty vs Imageless Augmented Reality Assisted Total Knee Arthroplasty | 2027-10-01 |
| NCT02766231Limacorporate S.p.aPhysica CR and Physica PS Clinical Trial | 2027-10-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 46 studies in Osteoarthritis, Knee with a site in Belgium, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Study in patients with knee osteoarthritis treated by embolization using NBGM200
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: embolization therapy
MSK embolization
Knee Injury and Osteoarthritis Outcome score (KOOS-12)
Knee Injury and Osteoarthritis Outcome score (KOOS-12) is to evaluate the pain, function and quality of life. The total score ranges from 0 to 100, where higher scores indicate better outcomes.
Time frame: 6 months post treatment
Visual Analog Scale(VAS)
Visual Analog Scale(VAS) is to evaluate the pain from 0 to 10. Higher scores indicate worse outcomes, representing more severe pain
Time frame: 6 months post treatment
Whole Organ Magnetic Resonance Imaging Score (WORMS)
Whole Organ Magnetic Resonance Imaging Score (WORMS) is a semi-quantitative scoring method for multi-feature, whole-organ evaluation of knee OA based on MRI. The total score ranges from 0 to 332, with higher scores indicating worse outcomes.
Time frame: 6 months post treatment
Started Apr 2025 (actual). Primary completion is estimated for Feb 2027, 22 months after the start.
Of 139 industry-sponsored interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 34. This study's planned 22 months is above that.
Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Next Biomedical Co., Ltd.